Ultragenyx Pharmaceutical Inc’s recently made public that its President & CEO KAKKIS EMIL D unloaded Company’s shares for reported $0.5 million on Dec 30 ’24. In the deal valued at $42.23 per share,11,727 shares were sold. As a result of this transaction, KAKKIS EMIL D now holds 2,183,985 shares worth roughly $91.88 million.
Then, KAKKIS EMIL D bought 11,727 shares, generating $495,264 in total proceeds.
Before that, KAKKIS EMIL D sold 8,273 shares. Ultragenyx Pharmaceutical Inc shares valued at $413,650 were divested by the President & CEO at a price of $50.00 per share. As a result of the transaction, KAKKIS EMIL D now holds 2,195,712 shares, worth roughly $92.37 million.
Goldman upgraded its Ultragenyx Pharmaceutical Inc [RARE] rating to a Buy from a a Neutral in a research note published on June 06, 2024; the price target was increased to $67 from $56. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late April with a ‘”an Outperform”‘ rating. Wells Fargo began covering RARE with “an Overweight” recommendation on December 08, 2023.
Price Performance Review of RARE
On Friday, Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] saw its stock fall -3.62% to $42.07. Over the last five days, the stock has gained 2.24%. Nevertheless, the stocks have fallen -12.99% over the past one year. While a 52-week high of $60.37 was reached on 01/07/25, a 52-week low of $37.02 was recorded on 01/02/25. SMA at 50 days reached $46.67, while 200 days put it at $47.60.
Levels Of Support And Resistance For RARE Stock
The 24-hour chart illustrates a support level at 41.19, which if violated will result in even more drops to 40.32. On the upside, there is a resistance level at 43.33. A further resistance level may holdings at 44.60. The Relative Strength Index (RSI) on the 14-day chart is 38.36, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.36, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 67.37%. Stochastics %K at 49.65% indicates the stock is a holding.
How much short interest is there in Ultragenyx Pharmaceutical Inc?
A steep rise in short interest was recorded in Ultragenyx Pharmaceutical Inc stocks on 2024-12-13, growing by 0.37 million shares to a total of 3.71 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 3.35 million shares. There was a rise of 9.9%, which implies that there is a positive sentiment for the stock.
